Katharina Hopp

This study constructs a cross-model spatial and single-cell atlas of PKD, identifying Spp1 (osteopontin) as a conserved driver of disease progression through its signaling to Ly6clo monocytes.

This study tests DFMO, an FDA-approved drug, in a mouse model of ADPKD and finds it reduces kidney cyst growth and improves kidney health.

The paper identifies three epithelial cyst types in ADPKD using single-nucleus RNA sequencing and machine learning, showing their association with therapeutic response.

This study shows that IDO1 inhibition reduces ADPKD severity by altering the cystic immune microenvironment.